[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results

Abstract

Background [177Lu]Lu-DOTA-ZOL has shown promising results from the dosimetry and preclinical aspects, but data on its role in the clinical efficacy are limited. The objective of this study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-ZOL as a bone pain palliation agent in patients experiencing pain due to skeletal metastases from various cancers. Methods In total, 40 patients experiencing bone pain due to skeletal metastases were enrolled in this study. The patients were treated with a mean cumulative dose of 2.1 ± 0.6 GBq (1.3–2.7 GBq) [177Lu]Lu-DOTA-ZOL in a median follow-up duration of 10 months (IQR 8–14 months). The primary outcome endpoint was response assessment according to the visual analogue score (VAS). Secondary endpoints included analgesic score (AS), global pain assessment score, Eastern Cooperative Oncology Group Assessment performance status (ECOG), Karnofsky performance status, overall survival, and safety assessment by the National Cancer Institute’s Common Toxicity Criteria V5.0. Results In total, 40 patients (15 males and 25 females) with a mean age of 46.6 ± 15.08 years (range 24–78 years) were treated with either 1 (N = 15) or 2 (N = 25) cycles of [177Lu]Lu-DOTA-ZOL. According to the VAS response assessment criteria, complete, partial, and minimal responses were observed in 11 (27.5%), 20 (50%), and 5 patients (12.5%), respectively with an overall response rate of 90%. Global pain assessment criteria revealed complete, partial, minimal, and no response in 2 (5%), 25 (62.5%), 9 (22.5%), and 4 (10%) patients, respectively. Twenty-eight patients died and the estimated median overall survival was 13 months (95% CI 10–14 months). A significant improvement was observed in the VAS, AS, and ECOG status when compared to baseline. None of the patients experienced grade III/IV haematological, kidney, or hepatotoxicity due to [177Lu]Lu-DOTA-ZOL therapy. Conclusion [177Lu]Lu-DOTA-ZOL shows promising results and is an effective radiopharmaceutical in the treatment of bone pain due to skeletal metastases from various cancers.

Altered static functional network connectivity predicts the efficacy of non-steroidal anti-inflammatory drugs in migraineurs without aura

“…Patients were asked to record a headache diary about headache intensity (VAS score) before and 2 h after drug intake within 3 months after scanning. According to the criteria, the complete response, partial response, minimal response, and no response were classified as > 75% reduction, 50–75% reduction, 25–50% reduction, and < 25% reduction in VAS scores, respectively ( Yadav et al, 2020 ). The response to NSAIDs was defined as a 50% or greater reduction in pain intensity from pre-treatment level to post-treatment level at least 2 times.…”

Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy

“…Aside from this specific study, the clinical use of [ 68 Ga]Ga-DOTAZOL is also reported for the selection and follow-up of patients considered for TRT with [ 177 Lu]Lu-DOTAZOL [ 182 , 183 , 184 ].…”

Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases

“…These studies also revealed higher absorption of the dose by the trabecular bone in patients who received 177 Lu-DOTA-ZOL vs. 177 Lu-EDTMP, but the dose absorbed by critical organs was much lower for the former radiopharmaceutical. Recently, the safety and efficacy of 177 Lu-DOTA-ZOL in 40 patients with metastatic bone disease was evaluated [ 112 ]. Eligible subjects received 0.13 GBq of 177 Lu-DOAT-ZOL at monthly intervals and then were monitored for a 12-week period after therapy.…”